Diseases
The development of biosimilars offers a cost-effective solution for treating immune-related diseases, but regulatory inconsistencies across different countries and agencies hinder their adoption. According to researchers at Wake Forest University School of Medicine, the current regulatory framework for biologics and biosimilars is complex and varies across the US, Europe, and
Diseases
The US Food and Drug Administration (FDA) has approved Insmed Incorporated's (Nasdaq: INSM) first-in-class treatment, BRINSUPRI (brensocatib), for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. This approval marks a significant advancement in the management of NCFB, a chronic and progressive disease affecting hundreds
Diseases
The US Food and Drug Administration (FDA) has granted Fast Track Designation to AAVantgarde Bio's gene therapy program, AAVB-039, for the treatment of Stargardt disease secondary to biallelic mutation in ABCA4. This designation acknowledges the urgent unmet need and potential of AAVB-039, a therapy that addresses the underlying
Securities law
Agios Pharmaceuticals, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission on August 4, 2025, disclosing significant information regarding PYRUKYND, a treatment for rare diseases. The report addresses recent data from the U.S. Food and Drug Administration's Adverse Event Reporting System, received
Securities law
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG) concerning allegations that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to
Securities law
A federal securities class action has been filed against PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG), alleging that the Company and its executives made false and/or misleading statements regarding the efficacy and safety of PGN-EDO51, a treatment for Duchenne Muscular Dystrophy (DMD). The complaint
Securities law
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (NASDAQ: PEPG) on behalf of investors who suffered losses exceeding $50,000 in the company's securities. The investigation focuses on the alleged false and misleading statements made by PepGen and its
Securities law
Coya Therapeutics, a biopharmaceutical company, has disclosed that the U.S. Food and Drug Administration (FDA) is unable to meet its initial review goal date for the Investigational New Drug (IND) Application for its planned clinical study, entitled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week
Securities law
Investors who suffered losses in Replimune Group, Inc. may have grounds for a securities class action lawsuit. Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune. The firm reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff
Securities law
PepGen Inc. and its executives are being investigated by Faruqi & Faruqi LLP for potential claims related to false and misleading statements regarding the effectiveness and safety of PGN-EDO51, the CONNECT2 study, and clinical, regulatory, and commercial prospects of the company. The investigation focuses on the company's statements
Securities law
The law firm Faruqi & Faruqi is investigating potential claims against PepGen Inc. (NASDAQ: PEPG), a biotechnology company, and its executives for alleged violations of federal securities laws. The investigation follows a federal securities class action filed against the company, alleging that PepGen and its executives made false and/or
Securities law
Sarepta Therapeutics, Inc., a biopharmaceutical company, has announced a clinical hold on its investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) by the U.S. Food and Drug Administration (FDA). The hold includes four product candidates: SRP-9003, SRP-9004, SRP-6004, and SRP-9005. This decision follows the company'
